GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in ...

Announce initial clinical data from Cohort 1 in the Phase 1/2 trial of PM359 for p47 phox CGD in 2025. The initial readout ...

Title: ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic ...

Dr. Falk Pharma’s norucholic acid (NCA) drug has demonstrated potential in a Phase III trial for primary sclerosing ...

Liver disease patients are falling through the cracks and not getting the treatment they need. Support from people with lived experience of disease could bridge the gap.

High-fructose corn syrup, prevalent in many processed foods, is a simple carbohydrate that offers minimal nutritional value and contributes to obesity ...

By analysing DNA from blood samples, Tvaster Genkalp is working to make cancer diagnostics more accessible, accurate, and ...

A recent study found that six cardiometabolic risk groups previously identified in middle-aged individuals can also be applied to older adults without diabetes. Using data from the KORA F4/FF4 study ...

Obicetrapib provided dramatic reductions in LDL cholesterol, without noticeable side effects, in a phase III trial of ...

A promising target for rare liver cancer, a functional cure for multiple myeloma — and support for people with ovarian cancer.

It's a key component of weight lost and diabetes drugs and researchers have found it can do wonders for those who have ...

An experimental new treatment is showing early promise in the fight against liver fibrosis – a serious and often silent ...